The world's first vaccine against dengue, developed by French drugmaker Sanofi, has shown the ability to protect against disease caused by three of four dengue virus strains in a keenly awaited clinical trial in Thailand.
Sanofi said on Wednesday the proof of efficacy was "a key milestone" in the 70-year quest to develop a viable dengue shot, adding the results also confirmed the safety profile of the vaccine candidate.
The mosquito-borne disease - also known as "breakbone fever" - is a threat to nearly 3 billion people and is caused by four different types of virus, none of which confers immunity from the others.
Sanofi's vaccine generated an antibody response for all four dengue virus types, but evidence of protection was only demonstrated against three of the four circulating in Thailand. Sanofi said researchers were carrying out analyses to understand the lack of protection for the fourth serotype.
The company's vaccine unit, Sanofi Pasteur, has already invested 350 million euros ($423 million) in a new French factory to make the three-dose vaccine and believes its product could generate 1 billion euros in yearly sales.
But uptake of the vaccine will depend on precisely how well doctors believe it can protect populations at risk in fast-expanding tropical cities from Rio to Manila, as well as travelers.
Sanofi gave no details on the level of protection in a brief statement. The full data are now being reviewed by scientific experts and public health officials, with detailed results to be published later this year.
Sanofi previously said it planned to present the findings at the annual meeting of the American Society of Tropical Medicine and Hygiene in Atlanta in November.
Large-scale late-stage Phase III clinical studies with 31,000 participants are under way with Sanofi's vaccine in 10 countries in Asia and Latin America.
MSF is discussing whether to shorten some Ebola assignments from their current duration of four to six weeks
The recent surge in cases, now numbering 32 since the start of October, has been focused in Riyadh and the western city of Taif
The meeting organized by ALBA, a bloc of leftist-governed countries, aims to coordinate a regional strategy on the prevention and control of Ebola
U.N. Secretary-General Ban Ki-moon has voiced his regret that health workers returning from Ebola-stricken countries in West Africa were quarantined.
In a research carried out in the U.S. reveals alarming findings about spending on illicit drugs -over $100 billion
The Township Owl Project takes juvenile birds rescued from perilous situations, such as when a building where they nested in is demolished, and gives them a new home and a new job
The three worst-hit countries of West Africa - Guinea, Liberia and Sierra Leone - account for the bulk, recording 4,912 deaths out of 10,114 cases
There are 883 confirmed cases of the deadly virus, out of which 319 people have died since 2012, the WHO says
WHO announces one million doses of Ebola vaccine to be produced in 2015
That pact would aim to improve on two decades of stuttering cooperation and rein in emissions of carbon dioxide blamed for a disruptive rise in temperatures
The World Health Organization last month urged the use of blood-derived products and serum from survivors.
Pentagon rapid-response Ebola medical team was scheduled to begin training at Fort Sam Houston in San Antonio, Texas
Extensively drug-resistant TB (XDR-TB), which is even more expensive and difficult to treat than multi drug-resistant (MDR-TB) strains, has now been reported in 100 countries around the world.
Device can be used in the field without special equipment, according to developers
The technique involved transplanting what are known as olfactory ensheathing cells into the patient's spinal cord and constructing a "nerve bridge" between two stumps of the damaged spinal column.
The meeting in Cuba is aimed at keeping Ebola at bay and it brings together senior officials from the ALBA bloc of nations